HC Wainwright Brokers Increase Earnings Estimates for Imunon

Imunon, Inc. (NASDAQ:IMNN) – Equities researchers at HC Wainwright lifted their Q1 2026 earnings estimates for Imunon in a research note issued to investors on Thursday, April 2nd. HC Wainwright analyst E. Bodnar now anticipates that the company will earn ($1.28) per share for the quarter, up from their previous forecast of ($1.29). The consensus estimate for Imunon’s current full-year earnings is ($1.68) per share. HC Wainwright also issued estimates for Imunon’s Q2 2026 earnings at ($1.16) EPS, Q3 2026 earnings at ($0.84) EPS, Q4 2026 earnings at ($1.05) EPS, FY2026 earnings at ($4.14) EPS, FY2027 earnings at ($2.12) EPS, FY2028 earnings at ($3.00) EPS, FY2029 earnings at ($1.84) EPS and FY2030 earnings at ($1.31) EPS.

Several other analysts have also recently commented on the stock. reissued a “buy” rating on shares of Imunon in a research note on Wednesday, January 7th. Weiss Ratings reissued a “sell (e+)” rating on shares of Imunon in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Reduce” and an average target price of $255.00.

Imunon Price Performance

IMNN opened at $3.12 on Tuesday. Imunon has a one year low of $2.52 and a one year high of $41.22. The company’s 50 day simple moving average is $3.14 and its 200-day simple moving average is $3.83. The stock has a market capitalization of $12.23 million, a P/E ratio of -0.39 and a beta of 2.13.

Imunon (NASDAQ:IMNN) last released its quarterly earnings results on Tuesday, March 31st. The company reported ($1.29) EPS for the quarter, beating the consensus estimate of ($1.43) by $0.14. The company had revenue of ($0.73) million for the quarter, compared to the consensus estimate of ($0.73) million.

Hedge Funds Weigh In On Imunon

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Armistice Capital LLC bought a new position in Imunon in the fourth quarter valued at approximately $1,017,000. DRW Securities LLC boosted its stake in Imunon by 6.9% in the fourth quarter. DRW Securities LLC now owns 58,830 shares of the company’s stock valued at $224,000 after acquiring an additional 3,803 shares during the last quarter. Finally, Riverview Capital Advisers LLC boosted its stake in Imunon by 193.3% in the third quarter. Riverview Capital Advisers LLC now owns 34,364 shares of the company’s stock valued at $176,000 after acquiring an additional 22,649 shares during the last quarter. 4.47% of the stock is owned by institutional investors.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.